Pharmadrug Inc
Change company Symbol lookup
Select an option...
LMLLF Pharmadrug Inc
CEIX CONSOL Energy Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
TNP-F Tsakos Energy Navigation Ltd
ANEB Anebulo Pharmaceuticals Inc
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc
Go


Based in Canada
Company profile

Pharmadrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics, cannabis and naturally derived approved drugs. The Company’s operations comprise the corporate division in Canada, the retail Smart Shop in the Netherlands, and the Online Slim Winkel business in the United States. The Company owns Sairiyo Therapeutics Inc. (Sairiyo), a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is developing its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of Covid-19 and rare cancers. The Company also owns Super Smart, building a vertically integrated retail business to elevate the use of functional mushrooms as natural-based medicines.

Closing Price
$0.0113
Day's Change
0.001 (9.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0113
Day's Low
0.0103
Volume
(Heavy Day)
Volume:
62,235

10-day average volume:
22,408
62,235

Display:

Providers:

UpdateCancel
6 providers
February 22, 2023
PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch

Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and...(Newsfile)

February 13, 2023
PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and...(Newsfile)

January 31, 2023
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and...(Newsfile)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.